Capula Management’s Moderna MRNA Stock Holding History

Capula Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,500	Closed	-$737K	–	991
2026 Q1	$737K	Buy	+14,500	New	+$676K	0.01%	423
2025 Q3	–	Sell	-8,530	Closed	-$235K	–	862
2025 Q2	$235K	Buy	+8,530	New	+$225K	﹤0.01%	336
2025 Q1	–	Sell	-5,914	Closed	-$246K	–	727
2024 Q4	$246K	Buy	+5,914	New	+$283K	﹤0.01%	283
2024 Q3	–	Sell	-817	Closed	-$97K	–	584
2024 Q2	$97K	Sell	817 -5,631	-87%	-$713K	﹤0.01%	413
2024 Q1	$687K	Buy	+6,448	New	+$650K	0.02%	159
2023 Q3	–	Sell	-5,347	Closed	-$596K	–	610
2023 Q2	$650K	Buy	5,347 +5,037	+1,625%	+$672K	0.02%	231
2023 Q1	$47.6K	Buy	+310	New	+$51.1K	﹤0.01%	654
2022 Q4	–	Sell	-8,133	Closed	-$962K	–	843
2022 Q3	$962K	Buy	+8,133	New	+$1.23M	0.01%	405
2021 Q4	–	Sell	-112	Closed	-$43K	–	573
2021 Q3	$43K	Sell	112 -500	-82%	-$184K	﹤0.01%	828
2021 Q2	$144K	Buy	+612	New	+$109K	﹤0.01%	718

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Capula Management's MRNA Position: Q2 2026 in Review

Capula Management sold out of Moderna (MRNA) in Q2 2026, closing a stake of 14,500 shares — an estimated $737K sold.

Capula Management first reported a position in MRNA in Q2 2021 and held it in 10 quarters. The position peaked at $962K in Q3 2022. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Capula Management reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Capula Management sold 14,500 Moderna shares in Q2 2026, an estimated $737K.
Capula Management first reported a position in Moderna in Q2 2021 and held it in 10 quarters.
Capula Management's Moderna position peaked at $962K in Q3 2022.
775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.